Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
2 hedge funds and large institutions have $0 invested in Melinta Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 33 closing their positions.
95% less funds holding
Funds holding: 37 → 2 (-35)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 33
100% less capital invested
Capital invested by funds: $584K → $0 (-$584K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$142K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$128K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$60K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$52K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$30K |
MLNT Hedge Fund Activity: Q1 2020 in Review
2 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q1 2020, worth a combined $0 — down 100% from $584K a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of MLNT and 1 opened new positions — a net loss of 32 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was MassMutual Private Wealth & Trust, opening a new position worth an estimated $16. The largest seller was Stifel Financial, exiting entirely with an estimated $142K sold.
- 2 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q1 2020, down from 37 in Q4 2019.
- Funds reported $0 of Melinta Therapeutics, Inc. Common Stock stock for Q1 2020, down 100% quarter-over-quarter.
- 1 fund opened new Melinta Therapeutics, Inc. Common Stock positions in Q1 2020 and 33 closed out, a net change of -32 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q1 2020 was MassMutual Private Wealth & Trust, an estimated $16 added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q1 2020 was Stifel Financial, an estimated $142K sold.
Based on aggregated 13F filings for Q1 2020.